BioCardia Extends Cash Runway to January 2027 After $5.1M ATM Raise; Program Now Exhausted

summarizeSummary

BioCardia extended its cash runway to January 2027 by raising $5.1 million through an ATM offering, which is now exhausted, leaving the company in immediate need of new capital.

check_boxKey Events · Financing and Capital Events · BCDA

• Cash Runway Extended

  The company's cash and cash equivalents of $4.1 million as of June 30, 2026, are projected to fund operations until January 2027, an extension from the previous estimate of June 2026.

• ATM Program Exhausted

  BioCardia sold 4,004,330 shares for gross proceeds of $5.084 million during Q2 2026, fully exhausting its At-The-Market (ATM) offering capacity. No further shares can be sold under this program.

• Ongoing Going Concern Warning

  Management continues to express substantial doubt about the company's ability to continue as a going concern beyond one year, highlighting the need for additional capital.

• Significant Dilution

  Shares outstanding increased from 10.76 million at December 31, 2025, to 14.98 million at June 30, 2026, primarily due to the ATM sales. An additional 8.6 million potentially dilutive securities (options, warrants, RSUs) remain outstanding.

auto_awesomeAnalysis · BCDA · Life Sciences

BioCardia's Q2 2026 report shows a critical, but temporarily improved, liquidity position. The company successfully raised $5.1 million through its At-The-Market (ATM) offering during the quarter, extending its cash runway from June 2026 to January 2027. This capital raise, while highly dilutive, was essential for continued operations. However, the ATM program is now fully exhausted, meaning BioCardia must secure new financing to fund operations beyond January 2027, maintaining substantial doubt about its ability to continue as a going concern. Investors should watch for new financing announcements.